💎 Fed’s first rate cut since 2020 set to trigger market. Find undervalued gems with Fair ValueSee Undervalued Stocks

Allergan Restasis patent-stoked selloff overdone - JPMorgan

Published 10/16/2017, 04:15 PM
© Reuters.  Allergan Restasis patent-stoked selloff overdone - JPMorgan
JPM
-
DBKGn
-
AGN
-
WFC
-
  • JPMorgan (NYSE:JPM)'s Chris Schott says today's selloff in Allergan (AGN -3.5%) after a Texas district court invalidated its RESTASIS patents is overdone considering the company's "very attractive fundamental story," upcoming catalysts and numerous pipeline readouts next year (OVERWEIGHT/$300).
  • Wells Fargo (NYSE:WFC)'s David Maris agrees saying a generic alternative won't be launched in the U.S. before the company's appeal runs its course, 2019 at the earliest (OUTPERFORM/$276).
  • Cowen's Ken Cacciatore adds that RESTASIS is now completely removed from the company's valuation (OUTPERFORM/$400).
  • Deutsche Bank (DE:DBKGn) has cut its price target to $251 from $262 after accounting for 90% sales erosion in 2019 and 5% per year thereafter.
  • Source: Bloomberg
  • Previously: U.S. court invalidates Allergan's Restasis patents; shares down 5% (Oct. 16)
  • Now read: Allergan Q3 2017: Earnings Preview


Original article

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.